[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-ablation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,62,93,123,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100467038","stereotactic-liver-ablation-assisted-with-intra-arterial-ct-hepatic-arteriography-and-ablation-confirmation-software-assessment-stereolab-100467038",false,"NCT05361551","Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)","Inclusion Criteria:\n\n1. Patients presenting with up to 5 colorectal liver metastasis measuring up to 5 cm who are referred to percutaneous ablation;\n2. Ability to completely cover the target tumor with at least a 5 mm ablation margin as determined per pre-procedure cross-sectional imaging;\n3. Distance to central bile ducts \\> 1 cm;\n4. Adequate glomerular filtration rate (GFR \\> 40) and no severe allergies to iodine contrast-media;\n5. Ability to understand and the willingness to sign written informed consent;\n6. Age \\> 18 years-old;\n7. Performance status 0-2 (Eastern Cooperative Oncology Group Classification \\[ECOG\\]);\n8. Expected survival \\> 12 months.\n\nExclusion Criteria:\n\n1. Use of other prior or concomitant local therapy at the target tumor(s).\n2. Active bacterial infection or fungal infection on the day of the ablation.\n3. Platelet \\\u003C 50,000\u002Fmm3.\n4. INR \\> 1.5\n5. Patients with uncorrectable coagulopathy.\n6. Currently breastfeeding or pregnant (latter confirmed by serum pregnancy test).\n7. Physical or psychological condition which would impair study participation.\n8. ASA (American Society of Anesthesiologists) score of ≥ 4.\n9. Any other loco-regional therapies at the target lesion(s).\n10. Anatomical variations in the arterial-hepatic blood supply of the liver that preclude the use of CTHA imaging.","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","To achieve adequate tumor treatment coverage with sufficient minimal ablation margins, several steps are required: firstly, it is critical to define tumor boundaries and extent on intra-procedural CT image; secondly, accurate planning, targeting, and confirmation of ablation probe placement within the tumor; thirdly, the use of an intra-procedural imaging assessment method to evaluate minimal ablation margins is required to define whether sufficient minimal ablation margins was obtained or if additional ablation is needed. Taking all together, those factors points to the need of having a high-precision ablation methodology for intra-procedural planning, monitoring, and ablation margin assessment. Currently, such methods are only utilized in isolation and the benefit of a combined and standardized procedure workflow is unknown. Therefore, our primary goal of this single-arm clinical trial is to investigate the technical efficacy of a high-precision liver ablation technique comprised by stereotactic-guidance, CT during hepatic arteriography-based imaging analysis, and computer-based software assessment of ablation margins for the treatment of patients referred to ablation for the treatment of primary and secondary liver cancers.",[25,26],"Liver Ablation","Hepatic","RECRUITING","2026-04-14",{"date":30,"type":31},"2026-04-17","ACTUAL",{"date":33,"type":31},"2023-02-21",{"date":35,"type":19},"2026-08-31",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":44,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100628259","clinical-study-on-the-safety-efficacy-and-exploration-of-immune-mechanisms-of-a-combined-multimodal-tumor-therapy-system-for-hepatic-malignancies-100628259","NCT07459309","Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;\n3. Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;\n4. Patient is intolerant to or refuses surgical resection;\n5. ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.\n\nExclusion Criteria:\n\n1. Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;\n2. Massive or diffuse hepatocellular carcinoma;\n3. Presence of vascular tumor thrombus or invasion of adjacent organs;\n4. History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;\n5. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;\n6. Refractory massive ascites, cachexia;\n7. Active infection, especially inflammatory conditions of the biliary system;\n8. Severe functional failure of major organs such as liver, kidney, heart, lung, and brain;\n9. Impaired consciousness, or inability to cooperate with treatment;\n10. Previous systemic treatments (e.g., chemotherapy) with an interval of less than 2 weeks and not having recovered from prior treatment: CTCAE 6.0 grade \\>1 (except for alopecia);\n11. Any other factors deemed by the investigator to make the subject unsuitable for participation or to affect the subject's involvement in the study.","80 Years",{"count":48,"type":19},20,[22],[51,25],"Liver Cancer (Primary and Metastatic)","NOT_YET_RECRUITING","2026-03-04",{"date":55,"type":31},"2026-03-09",{"date":57,"type":19},"2026-03-16",{"date":59,"type":19},"2027-12-31",{"name":61,"class":38},"Fudan University",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":39},"100622584","the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases-100622584","NCT07385521","The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases","A Retrospective Observational Study to Use Artificial Intelligence for Prediction of Disease REcurrence of COlorectal Cancer Liver METastasis After Hepatic Resection","AI-RECOLMET","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis (at final pathology) of liver metastases from colon or rectal adenocarcinoma\n* \\> 6 months of follow-up\n* no other concomitant neoplastic disease\n\nExclusion Criteria:\n\n* All subjects receiving hepatic resection but not fulfilling the inclusion criteria",{"count":71,"type":19},1000,"OBSERVATIONAL","Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Survival is primarily determined by stage of disease and the presence of metastases. The combination of chemotherapy and liver resection remains the treatment option with the highest survival benefit for patients with liver metastases from colorectal cancer, with surgery still being the only recognized potential curative treatment; surgical locoregional treatment can also be combined with thermal ablation to enhance the possibility of complete liver clearance. Despite significant improvements in prognosis, a large proportion of patients (almost half) will still experience recurrence following treatment. There is a clinical need to identify a priori patients who are different likely to develop disease recurrence after locoregional treatment (liver resection ± thermal ablation) and to respond differently to chemotherapy, in order to refine risk-based allocation of treatments and resources. Widespread digitalization of healthcare generates a large amount of data, and together with today accessible high-performance computing, artificial intelligence technologies can be applied to overcome the current limitations in estimating colorectal cancer liver metastases recurrence and response to locoregional and chemotherapy treatments, thus achieving better treatment allocation than current practice. All radiomic features can also help in training the neural network aimed at detecting liver metastases before they become visually detectable by the radiologist. Therefore, this study aims to evaluate whether a multifactorial machine learning model (including clinical and radiomic) can identify patients with colorectal cancer liver metastases with a high risk of progression after chemotherapy and recurrence after liver resection",[75,76,77,25],"Colorectal Liver Metastasis (CRLM)","Liver Resection","Hepatectomy",[79,80,77,81,82,83],"Colorectal liver metastases","Liver resection","Liver ablation","Machine learning (ML)","Artificial Intelligence (AI)","2026-01-29",{"date":86,"type":31},"2026-02-04",{"date":88,"type":31},"2025-02-19",{"date":90,"type":19},"2027-02-19",{"name":92,"class":38},"Francesco De Cobelli",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":39},"100607668","international-study-on-treatment-of-patients-with-metastatic-colorectal-liver-lesions-patients-with-ire-100607668","NCT07191548","International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE","Treatment of LIVER METastases From Colorectal Cancer by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study.","LIVERMET-IRE","Inclusion Criteria:\n\n* Patients aged 18 years and over, able to provide informed consent and with histological confirmation of a diagnosis of colorectal cancer from primary tumour.\n* Liver lesions demonstrating radiological characteristics (on magnetic resonance scan) of colorectal hepatic metastases without requirement for biopsy. In the setting of an intact liver, patients with up to four metastases ≤ 4cm in size are eligible for inclusion. In the setting of proposed resection plus ablation, up to two metastases ≤ 4cm in size. In the setting of recurrence after prior hepatectomy up to two metastases ≤ 4cm in size.\n* Eastern Co-operative Oncology Group (ECOG) Score ≤ 2.\n* Rockwood Frailty Score ≤ 3.\n* Serum bilirubin \\\u003C 30 µmol\u002FL.\n* Serum creatinine \\\u003C 150 µmol\u002FL.\n* Up to two lung metastases (\\\u003C 2cm in size permitted at enrolment).\n* Prior treatment with at least one course of systemic chemotherapy (± biologic agent) mandated. Chemotherapy protocol is not specified and is at clinician discretion.\n* Primary rectal tumour can remain in situ treated with radiotherapy\u002Fchemoradiotherapy according to tumour board recommendations. Primary colonic tumour can remain in situ.\n* No prior hepatic tumour ablation\n\nExclusion Criteria:\n\n* Patients involved in other research studies.\n* Inability to give informed consent.\n* Patients who are pregnant.\n* Accepted exclusions to IRE from consensus criteria including:\n* Platelet count \\\u003C 50x109 U\u002FL.\n* International normalised ratio (INR) for blood clotting \\> 1.7.\n* Prior hepatic tumour ablation.\n\nCardiovascular fitness related exclusions:\n\n* History of ventricular arrhythmia.\n* Implanted pacemaker or defibrillator.\n* Congestive cardiac failure NYHA Class ≥ 3.\n\nTumour-related exclusions:\n\n* Tumour ≥ 4 cm in size.\n* Advanced multi-site metastatic cancer (any of the following): peritoneal metastases (M1c), bone metastases, \\> 2 lung metastases, all segment involvement multiple liver metastases.\n* Jaundice (serum bilirubin \\> 30 µmol\u002FL).\n* MDT\u002Ftumour recommends use of thermal ablation instead of IRE for any given lesion.",{"count":18,"type":19},[22],"Procedural data will be recorded from patients with liver metastases from colorectal cancer who have received at least one course of systemic chemotherapy and who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation.",[105,25,106],"Colorectal Adenocarcinoma Metastatic in the Liver","Liver Cancer, Adult",[108,109,110,111,112],"irreversible electroporation","liver ablation","metastatic liver disease","nanoknife","liver ire registry","2025-10-08",{"date":115,"type":31},"2025-10-10",{"date":117,"type":19},"2026-02",{"date":119,"type":19},"2029-02",{"name":121,"class":122},"Angiodynamics, Inc.","INDUSTRY",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":20,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":140,"locationsCount":39},"100607759","international-study-on-treatment-of-liver-hcc-patients-with-ire-100607759","NCT07192731","International Study on Treatment of Liver (HCC) Patients With IRE","Treatment of LIVER-limited HepatoCellular Carcinoma (HCC) in Patients With Preserved Liver Function by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study","LIVERHCC-IRE","Inclusion Criteria:\n\n* Patients aged 18 years and over, able to provide informed consent and with clinical diagnosis of an HCC. Tissue confirmation of HCC prior to treatment is not standard of care and is therefore not required for this study.\n* Child-Pugh A up to A6.\n* Eastern Co-operative Oncology Group (ECOG) Score ≤ 2.\n* Rockwood Frailty Score ≤ 3.\n* Serum bilirubin \\\u003C 30 µmol\u002FL.\n* Serum creatinine \\\u003C 150 µmol\u002FL.\n* No extrahepatic metastases\n* IRE can be used for up to 3 tumours \\\u003C 3cm in size. Other forms of ablation can be combined with IRE in the same sitting but not for the same lesion. IRE can also be combined with surgical resection.\n\nExclusion Criteria:\n\nGeneral:\n\n* Patients involved in other research studies.\n* Patients under the age of 18 years.\n* Inability to give informed consent.\n* Patients who are pregnant.\n* Child-Pugh B or C.\n* Patients with an ECOG status of \\> 2 at time of recruitment.\n* Rockwood Frailty Score \\> 3\n* Impaired renal function (serum creatinine \\> 150 µmol\u002FL)\n* Accepted exclusions to IRE from consensus criteria including:\n* Platelet count \\\u003C 50x109 U\u002FL.\n* International normalised ratio (INR) for blood clotting \\> 1.7.\n* Prior hepatic tumour ablation.\n\nCardiovascular fitness related exclusions:\n\n* History of ventricular arrhythmia.\n* Implanted pacemaker or defibrillator.\n* Congestive cardiac failure NYHA Class ≥ 3.\n\nTumour-related exclusions:\n\n* Tumour ≥ 3 cm in size.\n* Extrahepatic metastatic disease.\n* Jaundice (serum bilirubin \\> 30 µmol\u002FL).\n* MDT recommends use of thermal ablation for any given lesion.",{"count":18,"type":19},[22],"Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation",[135,25,106],"Hepatocellular Carcinoma (HCC)",[108,109,111,112],{"date":115,"type":31},{"date":117,"type":19},{"date":119,"type":19},{"name":121,"class":122},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":39},"100609223","comparison-of-transcutaneous-and-arterial-carbon-dioxide-sampling-during-jet-ventilation-a-prospective-study-on-patients-undergoing-percutaneous-liver-tumour-radiofrequency-ablation-100609223","NCT07211763","Comparison of Transcutaneous and Arterial Carbon Dioxide Sampling During Jet Ventilation, a Prospective. Study on Patients Undergoing Percutaneous Liver Tumour Radiofrequency Ablation","Transcutaneous Versus Arterial Carbon Dioxide Monitoring During Jet Ventilation","Inclusion Criteria:\n\n* adult patients undergoing percutaneous RF liver tumour ablation requiring jet ventilation\n\nExclusion Criteria:\n\n* disease or condition. not compatible with jet ventilation",{"count":149,"type":19},100,"The study aims to compare the readings from two methods of monitoring carbon dioxide levels during jet ventilation when normal end-tidal monitoring is not possible. During jet ventilation it is technically not possible to monitor the levels of carbon dioxide in exhaled air as is the standard in preoperative care. We will compare transcutaneous (through the skin) monitoring to an arterial blood. sample. Both transcutaneous monitoring and arterial monitoring is currently used as the standard for this patient group at our institution. By collecting data prospectively we can evaluate if there. are discrepancies based on monitoring method. All patients will be treated per standard preoperative protocol and only patients consenting to participate will contribute data to the comparison and statistical analysis.",[25,152],"High Frequency Jet Ventilation",[154],"jet ventilation","2025-10-01",{"date":113,"type":31},{"date":158,"type":31},"2025-04-01",{"date":160,"type":19},"2026-07",{"name":162,"class":38},"Sahlgrenska University Hospital"]